Answers are grounded in this paper and cite their sources.
Many human diseases mediated by inflammation, allergy, autoimmunity, metabolic dysfunction, degeneration, apoptosis, fibrosis, and malignancy await new treatments. The cellular responses in these diseases depend on signal transduction and gene transcription. On average, one human cell displays 2, 000 proteins with distinct structural and functional characteristics. Cell-penetrating peptides, termed Nuclear Transport Checkpoint Inhibitors (NTCIs), were developed to analyze and control the nuclear transport of these intracellular proteins during inflammatory and metabolic responses. The NTCI peptides comprise two parts: the cell-penetrating module and the intracellular target recognition module. The prototypical cell-penetrating peptide named SN50, and its more active congeners, cSN50 and cSN50.1, cross directly the cell membrane phospholipid bilayer bypassing membrane receptors and transporters. Once inside the cell, the NTCI peptides lock in on their targets, the nuclear transport adaptors termed importins, aka karyopherins, that operate the nuclear gateway. The imposed nuclear transport blockade stops the genomic response to proinflammatory, metabolic, proapoptotic, prooncogenic, and neurodegenerative signaling and subsequent gene transcription in the cell’s nucleus. The cell-penetrating NTCI peptides were tested in isolated human and animal cells as well as in the preclinical models of human diseases. Among them, sepsis, the life-threatening stage of out-of-control infections that afflict annually est. 14 million patients world-wide with 11 million deaths, was controlled by the single cell-penetrating cSN50.1 peptide combined with anti-microbial agent in the preclinical model. The survival of antibiotic treated animals almost doubled. Such a gain in survival due to cSN50.1 peptide treatment was linked to the suppression of thousands of genes in the lungs and kidneys, the sites of acute respiratory distress syndrome (ARDS) and the acute kidney failure (AKI), respectively. Other difficult to treat diseases were also controlled by the cell-penetrating SN50 peptide in preclinical studies. They included: (i) life-threatening liver injury in endotoxic shock and alcoholic intoxication, (ii) traumatic brain injury and other neurologic disorders, (iii) Type 1(juvenile) diabetes, wherein the need for insulin therapy was eliminated for an entire year after intense short-term therapy with the cSN50.1 peptide, (iv) Type 2diabetes and other signs of metabolic dysfunction (the weight gain, hyperlipidemia, fatty liver, and coronary atherosclerosis), which were suppressed after the8-week therapy with the cSN50.1 peptide, (v) autoinflammatory diseases affecting skin and bones, (vi) rheumatoid arthritis and other diseases of the joints,(vii) allergic inflammation-mediated diseases (atopic dermatitis, asthma, another manifestations of the “atopic march”), (viii) Disseminated Intravascular Coagulation, and (ix) hematologic and solid organs oncogenic diseases.
No takes yet. Share an insight, caveat, or question.
Hawiger et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: